Literature DB >> 29802567

TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer.

Rosekeila Simões Nomelini1, Luciano Eliziário Borges Júnior2, Cid Almeida de Lima2, Ana Flávia Carrijo Chiovato2, Douglas Côbo Micheli3, Beatriz Martins Tavares-Murta3, Eddie Fernando Candido Murta2.   

Abstract

The aims of the study were to compare the levels of tumor necrosis factor alpha (TNF-α) and its soluble type I (sTNF-R1) and type II (sTNF-R2) receptors detected in intracystic liquid and serum from benign and malignant ovarian neoplasms and to relate them to prognostic factors in epithelial ovarian cancer. The patients were divided into benign ovarian neoplasms (n = 46) and malignant ovarian neoplasms (n = 17). The serum and intracystic samples were collected before and during surgery for ovarian cyst, respectively. The levels of TNF-α, sTNF-R1, and sTNF-R2 were measured using ELISA. Results were compared with the Mann-Whitney test. Concentration of sTNF-R2 in the intracystic samples collected from the malignant neoplasia was significantly higher than that of the benign neoplasias (p = 0.02). Higher intracystic levels of sTNF-R2 exhibited a significant association with tumor differentiation grades 2 and 3 (p = 0.0087). There was no statistical significance in relation to serum levels. Tumor microenvironment levels of sTNF-R2 may represent a factor of poor prognosis in epithelial ovarian cancer.

Entities:  

Keywords:  Intracystic fluid; Ovarian neoplasm; Prognostic factor; Tumor necrosis factor alpha; Tumor necrosis factor receptor 1; Tumor necrosis factor receptor 2

Mesh:

Substances:

Year:  2018        PMID: 29802567     DOI: 10.1007/s10238-018-0508-3

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  9 in total

Review 1.  Genomic structure, induction, and production of TNF-beta.

Authors:  R L Turetskaya; S J Fashena; N L Paul; N H Ruddle
Journal:  Immunol Ser       Date:  1992

Review 2.  Comparative analysis of the structure and function of TNF-alpha and TNF-beta.

Authors:  B B Aggarwal
Journal:  Immunol Ser       Date:  1992

3.  Ultrasonographic criteria and tumor marker assay are good procedures for the diagnosis of ovarian neoplasia in preselected outpatients.

Authors:  E F C Murta; C S da Silva; R A S Gomes; B M Tavares-Murta; A L K O Melo
Journal:  Eur J Gynaecol Oncol       Date:  2004       Impact factor: 0.196

4.  Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer.

Authors:  Bozena Dobrzycka; Slawomir J Terlikowski; Magdalena Garbowicz; Wieslawa Niklińska; Piotr S Bernaczyk; Jacek Nikliński; Maciej Kinalski; Lech Chyczewski
Journal:  Folia Histochem Cytobiol       Date:  2009       Impact factor: 1.698

5.  Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.

Authors:  Robert L Giuntoli; Tonya J Webb; Alessia Zoso; Ophelia Rogers; Teresa P Diaz-Montes; Robert E Bristow; Mathias Oelke
Journal:  Anticancer Res       Date:  2009-08       Impact factor: 2.480

6.  Circulating levels of TNF-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer.

Authors:  Bozena Dobrzycka; Slawomir J Terlikowski; Oksana Kowalczuk; Maciej Kinalski
Journal:  Eur Cytokine Netw       Date:  2009-09       Impact factor: 2.737

7.  Distinct expression and localization of TNF system in ovarian carcinoma tissues: possible involvement of TNF-α in morphological changes of ovarian cancerous cells.

Authors:  Benjamin Piura; Liat Medina; Alex Rabinovich; Victor Dyomin; Ruthy Shaco Levy; Mahmoud Huleihel
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

8.  Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Liaquat Ali; Shashikant Lele; Michael A Huba; Song Liu; Kunle Odunsi
Journal:  Cancer Immun       Date:  2013-01-15

Review 9.  Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer.

Authors:  George Kouklakis; Eleni I Efremidou; Michael Pitiakoudis; Nikolaos Liratzopoulos; Alexandros Ch Polychronidis
Journal:  Drug Des Devel Ther       Date:  2013-03-27       Impact factor: 4.162

  9 in total
  5 in total

Review 1.  Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy.

Authors:  Juliane Medler; Kirstin Kucka; Harald Wajant
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

Review 2.  The Role of the Adipokine Resistin in the Pathogenesis and Progression of Epithelial Ovarian Cancer.

Authors:  Klaudia Parafiniuk; Wiktoria Skiba; Anna Pawłowska; Dorota Suszczyk; Aleksandra Maciejczyk; Iwona Wertel
Journal:  Biomedicines       Date:  2022-04-16

Review 3.  TNFR2: Role in Cancer Immunology and Immunotherapy.

Authors:  Yang Yang; Md Sahidul Islam; Yuanjia Hu; Xin Chen
Journal:  Immunotargets Ther       Date:  2021-04-21

Review 4.  Targeting TNFR2 in Cancer: All Roads Lead to Rome.

Authors:  Jingchao Bai; Bowen Ding; Hui Li
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

Review 5.  Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer.

Authors:  Muchun Li; Xiaozhen Zhang; Xueli Bai; Tingbo Liang
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.